Skip to main content

Table 2 Intervention model parameters. CrI credible interval

From: Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis

  Parameter Mean value (95% CI where applicable) Reference
Palivizumab
  Delay between administration and protection (days) Immediate (fixed) [16]
 ωpal Average period of protection (days) 150 (fixed) [16]
epal Efficacy on VHR infants (%) 33.8 (0.0–66.6)1 [16]
Long-acting monoclonal antibodies
  Delay between administration and protection (days) Immediate (fixed) [4]
 ωmab Average period of protection (days) 275 (fixed) [4]
eSmab Efficacy against symptomatic infection (%) 70.1 (52.3–81.0)2 [37]
eHmab Efficacy against hospitalisation (%) 78.4 (51.9–90.3)3 [37]
Childhood/elderly vaccine
dvac Delay between administration and protection (days) 11.4 (2.8–22.1)4 [38]
 ω Average period of protection (days) Same as post-infection immunity (1/ω) [38]
evac Efficacy against all infections (%) 83.0 (75.0–88.0)5 [38]
Novavax vaccine
d2mat Average period of protection (days) 133.5 (119.6–146.1) Same as maternally derived immunity
eSmat Efficacy against symptomatic infection (%) 41.4 (4.1–64.2)6 [5]
eHmat Efficacy against hospitalisations (%) 53.5 (23.0–71.9)7 [5]
  1. Fitted distributions
  2. 1Gamma (3.7623, 0.0898)
  3. 2W(11.898, 0.732)
  4. 3W(11.611, 0.819)
  5. 4W(2.42, 12.87)
  6. 5W(31.464, 0.845)
  7. 6W(3.327, 0.461)
  8. 7W(5.354, 0.580)